On September 15, 2021, the SEC announced it had paid out $4 million and about $110 million to two whistleblowers who provided information and assistance
Sesen Bio, Inc. (SESN) Hid Information Relating to the Failure of its Clinical Trials for Vicineum On December 21, 2020, Sesen Bio announced it had
loanDepot, Inc. (LDI) Materially Misrepresented its Business Prospects in Connection with its IPO loanDepot, Inc. held its initial public offering (“IPO”) on February 16, 2021.
Acquisition of Inovalon Holdings, Inc. (INOV) by Nordic Capital and Others May Not Be in Shareholders’ Best Interests According to the Proxy Statement released on
The Boston Beer Company, Inc. (SAM) Failed to Disclose Deteriorating Sales, Inventory Write-offs, and Shortfall Fees On April 22, 2021, Boston Beer announced first
Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B Longeveron conducted its initial public offering (“IPO”) on February 12, 2021, issuing 2.66
Waterdrop Inc. (WDH) Materially Misrepresented its Revenue Growth and Increased Customer Base in its IPO Documents Waterdrop Inc. conducted its initial public offering (“IPO”)
Annovis Bio, Inc. (ANVS) Materially Misrepresented the Outcome of its ANVS401 Clinical Trials According to a class action complaint filed on behalf of Annovis Bio,
Live Ventures Inc. (LIVE) Made Misleading Statements Regarding its Business, Operations, and Prospects Between December 28, 2016 and August 3, 2021, defendants made materially
Attorney Advertising. Past results do not guarantee a similar outcome.
Disclaimer | Site Map | Privacy Policy
© 2021 – Robbins LLP
